Indication
- All patients receiving kidney and/or pancreas transplants
Dose
- 20mg given at induction of anaesthetic
- 20mg given on day 4 post transplant
Reconstitution
Administration
There are two possible routes of administration
- Intravenous bolus injection
- Intravenous infusion over 20-30 minutes (final volume of at least 50ml using sodium chloride 0.9% or dextrose 5%.)
Compatibility
Basiliximab should not be mixed with other medicines/substances and should always be given through a separate infusion line.
Adverse Effects
Severe acute hypersensitivity reactions have been observed - including anaphylactoid-type reactions - both on initial exposure and re-exposure to basiliximab. If severe hypersensitivity reaction occurs, therapy with basiliximab must be permanently discontinued and no further dose administered.
Side Effects
Basiliximab does not appear to add to the background of side effects seen in organ transplantation patients as a consequence of their underlying disease and concurrent administration of immunosuppressants.
Up to top
| (no previous) | >> Prednisolone |
